Contributions
Abstract: EP1324
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Paediatric MS
Introduction: acquired demyelination syndromes (ADS) represent a group of inflammatory disorders of the central nervous system (CNS) such as Multiple Sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), acute disseminating encephalomyelitis (ADEM), clinically isolated syndromes (CIS) and the recently described Myelin Oligodendrocyte Glycoprotein antibody (MOG) associated disease. ADS is rare in childhood and its prevalence is unknown in Brazil.
Objective: to describe the demographic and clinical aspects of pediatric ADS patients in a Brazilian center.
Methods: medical records review from patients followed at pediatric neuroimmunology clinic of Hospital das Clinicas, University of São Paulo-Brazil from january 2010 until december 2017. All patients whose symptoms started before 18 years of age and fulfilled International Pediatric Multiple Sclerosis Study Group (IPMSSG) current diagnostic criteria for MS, NMOSD, ADEM, CIS were included in addition to patients with MOG-IgG seropositivity.
Results: 150 patients were identified, 145 were analyzed (5 missing data): 80 were females (55,1%); median age of onset was 14 (1-17) years. 61 (42%) patients were tested for autoantibodies (MOG-IgG and aquaporin4-IgG). MS patients: 75 (52%), all recurrent course. NMOSD patients: 26 (18%), 18 were aquaporin4-IgG positives (69%), all recurrent; 5 were MOG-IgG positives (19%), 4 recurrent; 3 were double seronegatives. ADEM patients: 11 (7,5%), all monophasic. Optic neuritis (ON) patients: 15 (10%), 8 monophasic. Transverse myelitis (TM) patients: 9 (6%), 7 monophasic. CIS patients, other than ON and TM: 8 (5,5%), all monophasic. One patient with MOG-IgG had leukodystrophy-like phenotype.
Conclusions: most patients had recurrent ADS (75%) and MS was the most common. Autoantibodies tested in some patients revealed 19% of seropositivity and MOG-IgG patients showed heterogeneous clinic manifestation.
Disclosure: Renata Barbosa Paolilo: received grants related to congress meetings from Biogen and Roche. José Albino da Paz: nothing to disclose. Samira Luisa Apostolos Pereira: received grants related to congress meetings from Genzyme and Roche. Carolina de Medeiros Rimkus: nothing to disclose. Ana Luiza Camara Araujo: nothing to disclose. Dagoberto Callegaro: received grants related to congress meetings from Genzyme and Roche. Douglas Kazutoshi Sato: CAPES/Brasil, Japan Society of Science. Speaker for Merck, Shire, TEVA.
Abstract: EP1324
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Paediatric MS
Introduction: acquired demyelination syndromes (ADS) represent a group of inflammatory disorders of the central nervous system (CNS) such as Multiple Sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), acute disseminating encephalomyelitis (ADEM), clinically isolated syndromes (CIS) and the recently described Myelin Oligodendrocyte Glycoprotein antibody (MOG) associated disease. ADS is rare in childhood and its prevalence is unknown in Brazil.
Objective: to describe the demographic and clinical aspects of pediatric ADS patients in a Brazilian center.
Methods: medical records review from patients followed at pediatric neuroimmunology clinic of Hospital das Clinicas, University of São Paulo-Brazil from january 2010 until december 2017. All patients whose symptoms started before 18 years of age and fulfilled International Pediatric Multiple Sclerosis Study Group (IPMSSG) current diagnostic criteria for MS, NMOSD, ADEM, CIS were included in addition to patients with MOG-IgG seropositivity.
Results: 150 patients were identified, 145 were analyzed (5 missing data): 80 were females (55,1%); median age of onset was 14 (1-17) years. 61 (42%) patients were tested for autoantibodies (MOG-IgG and aquaporin4-IgG). MS patients: 75 (52%), all recurrent course. NMOSD patients: 26 (18%), 18 were aquaporin4-IgG positives (69%), all recurrent; 5 were MOG-IgG positives (19%), 4 recurrent; 3 were double seronegatives. ADEM patients: 11 (7,5%), all monophasic. Optic neuritis (ON) patients: 15 (10%), 8 monophasic. Transverse myelitis (TM) patients: 9 (6%), 7 monophasic. CIS patients, other than ON and TM: 8 (5,5%), all monophasic. One patient with MOG-IgG had leukodystrophy-like phenotype.
Conclusions: most patients had recurrent ADS (75%) and MS was the most common. Autoantibodies tested in some patients revealed 19% of seropositivity and MOG-IgG patients showed heterogeneous clinic manifestation.
Disclosure: Renata Barbosa Paolilo: received grants related to congress meetings from Biogen and Roche. José Albino da Paz: nothing to disclose. Samira Luisa Apostolos Pereira: received grants related to congress meetings from Genzyme and Roche. Carolina de Medeiros Rimkus: nothing to disclose. Ana Luiza Camara Araujo: nothing to disclose. Dagoberto Callegaro: received grants related to congress meetings from Genzyme and Roche. Douglas Kazutoshi Sato: CAPES/Brasil, Japan Society of Science. Speaker for Merck, Shire, TEVA.